socalTECH

OCTOBER 26, 2009

Thousand Oaks-based Ceres , a developer of energy crops for the biofuels energy, has landed $4,989,144 in a grant from the Department of Energy, as part of a $151M effort to fund energy breakthroughs. The effort is targeted at creating feed stocks for biofuels projects, to displace oil and coal.

Thousand Oaks 171

Thousand Oaks Research Funding Develop 171

socalTECH

FEBRUARY 21, 2013

Xirrus , the wireless hardware provider based in Thousand Oaks, has just raised $10.1M in a funding round, part of an ongoing $11.0M funding, according to a regulatory filing by the company. Details on the funding have not yet been announced by the company.

Thousand Oaks 164

Thousand Oaks Conference Networking Capital 164

socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164

socalTECH

JULY 2, 2010

Thousand Oaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Source of the new funding was not disclosed. The filing indicates the round came from five investors.

Thousand Oaks 150

Thousand Oaks Equity Funding Capital 150

socalTECH

SEPTEMBER 26, 2012

Thousand Oaks-based Xirrus , the developer of high speed, high performance wireless networking hardware, has raised another big chunk of financing, saying today that it has raised $23.5M in a Series E funding round. Xirrus said the funding will go towards sales growth and its product.

Networking 153

Networking Thousand Oaks Sales Capital 153

socalTECH

NOVEMBER 17, 2017

Amgen Ventures , the venture investment arm of Thousand Oaks-based Amgen , is one of the new investors in precision oncology and medicine startup Syapse.

Thousand Oaks 113

Thousand Oaks Funding Software Capital 113

socalTECH

APRIL 29, 2021

Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.

Westlake Village 113

Westlake Village Thousand Oaks Funding CalTech 113

socalTECH

JANUARY 10, 2014

Thousand Oaks-based Atara Biotherapeutics announced this morning that it is in a second close of its Series B funding round, bringing its total raised in the funding to $52M. READ MORE>>. amgen lifescience disease renal capital venture biotherapeutics atara'

Thousand Oaks 147

Thousand Oaks Capital Funding Invest 147

socalTECH

AUGUST 31, 2011

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , has backed the developer of a biopharmaceutical aimed at treating irritable bowel syndrome, kidney disease, and diabetes.

Thousand Oaks 150

Thousand Oaks Venture Capital Capital Funding 150

socalTECH

MAY 8, 2012

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M

Thousand Oaks 140

Thousand Oaks Invest Venture Capital Platform 140

socalTECH

JULY 2, 2014

San Diego-based Ocean Aero , a developer of unmanned, autonomous marine vehicles, has scored funding from Thousand Oaks-based Teledyne , the companies said this morning. Financial terms of the investment were not disclosed. According to Teledyne, the investment also included a strategic partnership deal.

Thousand Oaks 147

Thousand Oaks Invest San Diego Design 147

socalTECH

JULY 8, 2010

Thousand Oaks-based Ceres , a developer of biofuels crop technology, said Thursday that it has completed a private offering of convertible preferred stock. The funding came from Artal Luxembourg, Ambergate Trust, Gimv, and other undisclosed investors. Ceres is developing improved seed varieties--including.

Thousand Oaks 140

Thousand Oaks Venture Capital Design Activity 140

socalTECH

MAY 9, 2018

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , is one of the investors in a Boston biotech company, Akili Interactive. Akili is developing digital medicine products aimed at treating cognitive dysfunction, including ADHD, multiple sclerosis, and depression. READ MORE>>.

Thousand Oaks 100

Thousand Oaks Funding Venture Capital Capital 100

socalTECH

MARCH 8, 2016

Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Lightstone Ventures also participated in the funding. Tizona is based in South San Francisco, and is developing treatments for cancer and autoimmune diseases.

Thousand Oaks 100

Thousand Oaks Funding Venture Capital Invest 100

socalTECH

APRIL 8, 2014

Thousand Oaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer. READ MORE>>. atara biotherapeutics renal disease lifescience amgen executive board'

Thousand Oaks 138

Thousand Oaks Invest Capital Funding 138

socalTECH

JANUARY 4, 2021

Thousand Oaks-based Teledyne Technologies said today that it has agreed to acquire FLIR Systems, which develops infrared cameras and similar technology, in a deal worth $8.0 Both companies develops sensors, cameras, and sensor systems. Both companies develops sensors, cameras, and sensor systems.

Thousand Oaks 113

Thousand Oaks Funding Technology Develop 113

socalTECH

DECEMBER 27, 2019

Whats happening in regions in our counties with startup and entrepreneurial activity, especially in the Conejo Valley (Calabasas to Thousand Oaks) is exciting. Many jobs have been created and companies have received funding through our efforts of supporting and bringing value to founders.

Startup 196

Startup Thousand Oaks Mentor Ventura 196

socalTECH

JUNE 17, 2010

a developer of high speed, analog semiconductors, has filed for an IPO, saying late Wednesday evening in a filing with the SEC it is looking to raise up to $115M in an IPO on the NYSE. Inphi is venture backed by Walden International, Tallwood, Mayfield Fund, and Samsung Electronics. In its S-1, the firm said it had net income of $7.3M

Westlake Village 133

Westlake Village Thousand Oaks Southern California .Net 133

socalTECH

JANUARY 9, 2017

Thousand Oaks-based Amgen is the lead investor in a round for San Francisco- and Bozeman, Montana-based SiteOne Therapeutics , SiteOne said on Friday. SiteOne said it raised $15M in a Series B funding round, which was led b Amgen, and also included Next Frontier Capital and insiders.

Thousand Oaks 100

Thousand Oaks Invest Capital Funding 100

socalTECH

OCTOBER 31, 2017

Thousand Oaks-based biotech giant a href="[link] said on Monday that it has agreed to acquire its joint venture with Kirin, Kirin-Amgen , in a deal worth $780M. The JV was created in 1984 as a 50-50 joint venture to fund global development of Amgen's EPOGEN, and later included the company's other pharmaceutical products.

Thousand Oaks 113

Thousand Oaks Startup Funding Help 113

socalTECH

JANUARY 7, 2016

Thousand Oaks-based biotech giant Amgen is the a new investor in a round for Alector , a developer of immuno-modulatory therapies for Alzheimer's disease and other neurogenerative disorders, which announced a $29.5M funding today. READ MORE>>.

Thousand Oaks 100

Thousand Oaks Google Research Funding 100

socalTECH

JULY 30, 2018

Thousand Oaks-based Amgen has returned as one of the investors in cancer therapeutis developer Sutro Biopharma , as part of an $85.4M funding round. in a Series E funding round. Sutro Biopharma is developing a piepline of cancer therapeutics, with the lead contact targeted at treating lymphoma and multiple myeloma.

Thousand Oaks 100

Thousand Oaks Invest Capital Funding 100

socalTECH

OCTOBER 9, 2015

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. In addition to Amgen, Adheron has received venture capital from Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, and SROne.

Thousand Oaks 100

Thousand Oaks Venture Capital Activity Capital 100

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M Akriveia Therapeutics said it is developing immunotherapeutic products that are specifically activated in the microenvironment of the tumor. in a Series A investment. READ MORE>>.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

DECEMBER 8, 2022

Thousand Oaks-based Dantari has raised $47M in its Series A funding, saying that it has launched a new, clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancers and other diseases.

Westlake Village 100

Westlake Village Thousand Oaks CalTech Funding 100

socalTECH

APRIL 29, 2014

How are you funding this project? This is really also funded because of Mike and my other project, the 101 incubator. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of Thousand Oaks.

Startup 262

Startup Competition Software Review UCLA 262

SoCal Delicious

APRIL 5, 2010

Developers say the ambitious Rice Depot Mercado project will be a mixed-use hub, drawing pedestrian residential traffic from the densely populated area around it. Smith name might ring the loudest bell today for the developer’s various philanthropic efforts. “Bud” Smith , is this year’s only posthumous winner.

Santa Barbara 53

Santa Barbara Thousand Oaks Oracle Ventura 53

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Morgan party. The firm has since pledged to help close the gender gap among biotech leadership.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 22, 2016

—Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

JUNE 10, 2016

Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. —More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67